세계의 악성 흑색종 치료 시장 보고서(2025년)

Malignant melanoma treatment involves medical interventions and therapies aimed at managing and potentially curing malignant melanoma, a type of skin cancer originating from melanocytes, the cells responsible for producing the skin pigment melanin. The treatment of malignant melanoma provides several critical advantages for the well-being and potential recovery of individuals diagnosed with this aggressive form of skin cancer.

The primary treatments for malignant melanoma include immunotherapy, radiation therapy, chemotherapy, and others. Immunotherapy is a medical treatment that utilizes the body's own immune system to combat diseases, including certain types of cancer. Indicated for treating lentigo malignant melanoma, acral lentiginous melanoma, nodular melanoma, and superficial spreading melanoma, these treatments are administered by various end-users such as hospitals, specialty clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The malignant melanoma treatment market research report is one of a series of new reports from The Business Research Company that provides malignant melanoma treatment market statistics, including malignant melanoma treatment industry global market size, regional shares, competitors with a malignant melanoma treatment market share, detailed malignant melanoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the malignant melanoma treatment industry. This malignant melanoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The malignant melanoma treatment market size has grown rapidly in recent years. It will grow from $7.21 billion in 2024 to $7.98 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to targeted therapies, patient awareness and education, collaborative research initiatives, regulatory approvals.

The malignant melanoma treatment market size is expected to see rapid growth in the next few years. It will grow to $11.93 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to personalized medicine, global health initiatives, expanded genomic profiling, value-based healthcare models, patient-centric approaches. Major trends in the forecast period include integration of artificial intelligence (AI), early detection technologies, real-world evidence and data analytics, precision medicine integration, combination therapies.

The forecast of 10.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. market by increasing the cost of immune checkpoint inhibitors and BRAF/MEK inhibitor combos sourced from Switzerland and Germany, thereby reducing oncology care affordability and elevating specialty pharmacy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising exposure to ultraviolet (UV) radiation is anticipated to drive the growth of the malignant melanoma treatment market in the future. Ultraviolet (UV) radiation is a type of electromagnetic radiation with wavelengths shorter than visible light but longer than X-rays. The development of malignant melanoma is significantly impacted by exposure to UV radiation, particularly UVA (315-400 nm) and UVB (280-315 nm). UV radiation can harm the DNA in skin cells, resulting in mutations that lead to uncontrolled growth and division of these cells, ultimately forming a tumor. For instance, in February 2023, the Melanoma Research Foundation, a U.S.-based organization, reported that the total number of melanoma cases in the United States in 2023 was 187,000, which marked a 7.3% increase to 200,651 in 2024. Additionally, in February 2024, the United States Environmental Protection Agency, a U.S. government agency, stated that skin cancer is the most prevalent cancer in the U.S., with unprotected UV exposure being the primary preventable risk factor, affecting one in five Americans during their lifetime. Consequently, the increasing exposure to ultraviolet (UV) radiation is propelling the growth of the malignant melanoma treatment market.

The rising incidence of melanoma is expected to contribute to the growth of the malignant melanoma treatment market in the future. Melanoma is a type of skin cancer that originates in melanocytes, the skin cells responsible for producing pigment. Treatment for melanoma typically involves the surgical removal of the tumor, and additional therapies, such as immunotherapy or targeted therapy, may be recommended depending on the cancer's stage and extent. For example, in February 2023, the Melanoma Research Foundation, a U.S.-based organization, reported that the total number of melanoma cases in the United States in 2023 was 187,000, which increased by 7.3% to reach 200,651 in 2024. Thus, the increasing incidence of melanoma is driving the growth of the malignant melanoma treatment market.

Prominent players in the malignant melanoma treatment market are strategically focused on the development and approval of innovative drugs to fortify their market position. The increasing demand for more effective and safer treatments has led to a surge in drug approvals for malignant melanoma treatment, exemplified by Opdualag. This novel therapeutic option is a fixed-dose combination featuring two immunotherapy drugs, nivolumab and relatlimab-rmbw, designed to address unresectable or metastatic melanoma. Bristol Myers Squibb, a leading US-based pharmaceutical company, obtained approval for Opdualag from the US Food and Drug Administration in March 2022. Administered as a single intravenous infusion, Opdualag represents a first-in-class treatment, providing a groundbreaking approach for adult and pediatric patients aged 12 or older with metastatic or unresectable melanoma. Relatlimab-rmbw, a human IgG4 monoclonal antibody targeting the LAG-3 receptor, complements nivolumab in this fixed-dose combination. Opdualag's successful launch marks a significant addition to Bristol Myers Squibb's portfolio of cancer treatments, contributing to the company's overall growth.

In June 2022, Germany-based biotechnology firm Immatics N.V. joined forces with Bristol Myers Squibb to pioneer gamma delta allogeneic cell therapy programs. This collaboration is geared towards advancing cutting-edge cancer immunotherapies with the potential to revolutionize the treatment landscape for various cancers, including malignant melanoma. Bristol Myers Squibb, as a US-based pharmaceutical company, remains steadfast in its commitment to discovering, developing, and delivering innovative medicines to patients grappling with serious diseases, with a particular focus on advancing treatments for melanoma. The collaboration with Immatics N.V. underscores the company's dedication to advancing the field of cancer immunotherapy and exploring new avenues for enhanced treatment modalities.

Major companies operating in the malignant melanoma treatment market report are Johnson & Johnson Private Limited, Pfizer Inc., Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck & Co. Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Mylan N.V., Chugai Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Limited, bioMerieux SA, Ono Pharmaceutical Co. Ltd., Exelixis Inc., Array BioPharma Inc., Pierre Fabre Group, Clinigen Group, Iovance Biotherapeutics Inc., X4 Pharmaceuticals Inc., Mirati Therapeutics Inc., Moleculin Biotech Inc., Polynoma LLC, Enzon Pharmaceuticals Inc., Northwest Biotherapeutics Inc.

North America was the largest region in the malignant melanoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant melanoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the malignant melanoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The malignant melanoma treatment market consists of revenues earned by entities by providing services such as diagnosis and staging services, surgical services, medical treatments, genetic counseling, aesthetic services, and cosmetic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant melanoma treatment market also includes sales of aldesleukin, binimetinib, braftovi (encorafenib), cobimetinib fumarate, cotellic (cobimetinib fumarate), dabrafenib mesylate, dacarbazine, and encorafenib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Malignant Melanoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on malignant melanoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for malignant melanoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The malignant melanoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Immunotherapy; Radiation Therapy; Chemotherapy; Other Treatments
• 2) By Disease Type: Lentigo Maligna Melanoma; Acral Lentiginous Melanoma; Nodular Melanoma; Superficial Spreading Melanoma
• 3) By End-User: Hospitals; Specialty clinics; Other End Users
• Subsegments:
• 1) By Immunotherapy: Checkpoint Inhibitors; Cytokine Therapy; Oncolytic Virus Therapy
• 2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Radiation Therapy
• 3) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy Regimens
• 4) By Other Treatments: Targeted Therapy; Surgical Interventions; Clinical Trials For Novel Therapies
• Companies Mentioned: Johnson & Johnson Private Limited; Pfizer Inc.; Hoffmann-La Roche AG; Bayer AG; Novartis AG; Merck & Co. Inc.; GlaxoSmithKline plc; Bristol-Myers Squibb Company; Sanofi S.A.; AstraZeneca plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Daiichi Sankyo Company Limited; Mylan N.V.; Chugai Pharmaceutical Co. Ltd.; Sun Pharmaceutical Industries Limited; bioMerieux SA; Ono Pharmaceutical Co. Ltd.; Exelixis Inc.; Array BioPharma Inc.; Pierre Fabre Group; Clinigen Group; Iovance Biotherapeutics Inc.; X4 Pharmaceuticals Inc.; Mirati Therapeutics Inc.; Moleculin Biotech Inc.; Polynoma LLC; Enzon Pharmaceuticals Inc.; Northwest Biotherapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Malignant Melanoma Treatment Market Characteristics

3. Malignant Melanoma Treatment Market Trends And Strategies

4. Malignant Melanoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Malignant Melanoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Malignant Melanoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Malignant Melanoma Treatment Market Growth Rate Analysis
• 5.4. Global Malignant Melanoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Malignant Melanoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Malignant Melanoma Treatment Total Addressable Market (TAM)

6. Malignant Melanoma Treatment Market Segmentation

• 6.1. Global Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Other Treatments
• 6.2. Global Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lentigo Maligna Melanoma
• Acral Lentiginous Melanoma
• Nodular Melanoma
• Superficial Spreading Melanoma
• 6.3. Global Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty clinics
• Other End Users
• 6.4. Global Malignant Melanoma Treatment Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Cytokine Therapy
• Oncolytic Virus Therapy
• 6.5. Global Malignant Melanoma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Stereotactic Radiation Therapy
• 6.6. Global Malignant Melanoma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Traditional Chemotherapy Agents
• Combination Chemotherapy Regimens
• 6.7. Global Malignant Melanoma Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Surgical Interventions
• Clinical Trials For Novel Therapies

7. Malignant Melanoma Treatment Market Regional And Country Analysis

• 7.1. Global Malignant Melanoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Malignant Melanoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Malignant Melanoma Treatment Market

• 8.1. Asia-Pacific Malignant Melanoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Malignant Melanoma Treatment Market

• 9.1. China Malignant Melanoma Treatment Market Overview
• 9.2. China Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Malignant Melanoma Treatment Market

• 10.1. India Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Malignant Melanoma Treatment Market

• 11.1. Japan Malignant Melanoma Treatment Market Overview
• 11.2. Japan Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Malignant Melanoma Treatment Market

• 12.1. Australia Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Malignant Melanoma Treatment Market

• 13.1. Indonesia Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Malignant Melanoma Treatment Market

• 14.1. South Korea Malignant Melanoma Treatment Market Overview
• 14.2. South Korea Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Malignant Melanoma Treatment Market

• 15.1. Western Europe Malignant Melanoma Treatment Market Overview
• 15.2. Western Europe Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Malignant Melanoma Treatment Market

• 16.1. UK Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Malignant Melanoma Treatment Market

• 17.1. Germany Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Malignant Melanoma Treatment Market

• 18.1. France Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Malignant Melanoma Treatment Market

• 19.1. Italy Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Malignant Melanoma Treatment Market

• 20.1. Spain Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Malignant Melanoma Treatment Market

• 21.1. Eastern Europe Malignant Melanoma Treatment Market Overview
• 21.2. Eastern Europe Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Malignant Melanoma Treatment Market

• 22.1. Russia Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Malignant Melanoma Treatment Market

• 23.1. North America Malignant Melanoma Treatment Market Overview
• 23.2. North America Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Malignant Melanoma Treatment Market

• 24.1. USA Malignant Melanoma Treatment Market Overview
• 24.2. USA Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Malignant Melanoma Treatment Market

• 25.1. Canada Malignant Melanoma Treatment Market Overview
• 25.2. Canada Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Malignant Melanoma Treatment Market

• 26.1. South America Malignant Melanoma Treatment Market Overview
• 26.2. South America Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Malignant Melanoma Treatment Market

• 27.1. Brazil Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Malignant Melanoma Treatment Market

• 28.1. Middle East Malignant Melanoma Treatment Market Overview
• 28.2. Middle East Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Malignant Melanoma Treatment Market

• 29.1. Africa Malignant Melanoma Treatment Market Overview
• 29.2. Africa Malignant Melanoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Malignant Melanoma Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Malignant Melanoma Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Malignant Melanoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Malignant Melanoma Treatment Market Competitive Landscape
• 30.2. Malignant Melanoma Treatment Market Company Profiles
  • 30.2.1. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Malignant Melanoma Treatment Market Other Major And Innovative Companies

• 31.1. Merck & Co. Inc.
• 31.2. GlaxoSmithKline plc
• 31.3. Bristol-Myers Squibb Company
• 31.4. Sanofi S.A.
• 31.5. AstraZeneca plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Daiichi Sankyo Company Limited
• 31.10. Mylan N.V.
• 31.11. Chugai Pharmaceutical Co. Ltd.
• 31.12. Sun Pharmaceutical Industries Limited
• 31.13. bioMerieux SA
• 31.14. Ono Pharmaceutical Co. Ltd.
• 31.15. Exelixis Inc.

32. Global Malignant Melanoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Malignant Melanoma Treatment Market

34. Recent Developments In The Malignant Melanoma Treatment Market

35. Malignant Melanoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Malignant Melanoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Malignant Melanoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Malignant Melanoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer